Maternal Serum CA125 and CA15-3 Antigen Levels in Normal and Pathological Pregnancy

Bon, G.G.; Kenemans, P.; Verstraeten, A.A.; Go, Seon Myeong; Philipi, P.A.; Kamp, Gerard J. van; Geijn, H.P. van; Vugt, J.M.G. van

doi:10.1159/000053903

Cited by 58 publications

(50 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27,28 Given the demonstrated immunomodulatory roles of sMUC16, 7,8 we next determined whether there were any differences in the binding pattern of this mucin to immune cells in preeclamptic patients compared with healthy pregnant women. First, we confirmed the results of previous studies 22,29,30 that the serum CA125 levels were not significantly different between healthy pregnant women and preeclampsia patients (Fig. 5a).…”

Section: Muc16 Binding To Immune Cells Of Patients With Preeclampsiasupporting

confidence: 91%

“…22,25 We therefore monitored serum CA125 levels and immune cell bound sMUC16 in three women before and at 9 and 18 weeks of pregnancy. A gradual increase in serum CA125 was observed at 9 weeks of pregnancy.…”

Section: Nk Cell Bound Smuc16 Is Detected Even At Low Serum Ca125 Levelsmentioning

confidence: 99%

“…[18][19][20][21] Indeed, serum CA125 levels increase during pregnancy, 22 which is one of the reasons why serum CA125 cannot be used as an early diagnostic test exclusively for ovarian cancer. Considering our previous work on sMUC16 binding to PBMC and PFMC of ovarian cancer patients, 11,12 we investigated whether the mucin is also present on specific subsets of immune cells of pregnant women.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mining the Immune Cell Proteome to Identify Ovarian Cancer-Specific Biomarkers

Patankar¹

2012

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 15 FEB 2011 -14 FEB 2012 REPORT DATE 01-03-2012 REPORT TYPE Annual Report DATES COVERED TITLE AND SUBTITLE Mining the Immune Cell Proteome to Identify Ovarian Cancer-Specific Biomarkers Reportable Outcomes 2Conclusions 2 Supporting Documents 3-10Appendix 1 1 Introduction: The primary goal of this project is to identify biomarkers present in immune cells that can be used for the early detection and monitoring of ovarian cancer. Immune cells are continuously exposed to self and cancer antigens. These interactions result in alterations in the transcriptome and proteome of the immune cells. We are therefore proposing that the immune cells contain disease-specific biomarkers. In the current project we proposed to carry out in-depth proteomic analysis to identify the ovarian cancer-specific biomarkers.Body: Our studies are focused on three specific aims. In the first aim we are conducting experiments to clearly define the proteome of T cells, NK cells, B cells and monocytes.In the second aim we will identify specific changes in the proteomes of immune cells in response to defined antigens derived from ovarian cancer cells. Finally, in the third specific aim experiments will be conducted to compare the proteomes of immune cells isolated from peripheral blood and peritoneal fluid of ovarian cancer patients.We have now developed streamlined protocols using NKL cells that have allowed us to conduct bottom-up proteomics to identify the proteome of immune cells. Using these streamlined protocols, we have now completed the analysis of human NK cells. This analysis has allowed us to identify approximately 2000 individual proteins in the proteome of human NK cells. This analysis is now complete and we are currently preparing a manuscript on our results that will be submitted to Journal of Proteome research. These experiments address the objectives of Specific Aim 1.Next we have also obtained data on the proteome of immune cells that are exposed IL-2. These experiments were structured to provide initial data that would show the effect on immune proteomes of factors that the immune cells are likely to encounter in the tumor micr...

show abstract

Section: Muc16 Binding To Immune Cells Of Patients With Preeclampsiasupporting

confidence: 91%

Section: Nk Cell Bound Smuc16 Is Detected Even At Low Serum Ca125 Levelsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mining the Immune Cell Proteome to Identify Ovarian Cancer-Specific Biomarkers

Patankar¹

2012

View full text Add to dashboard Cite

show abstract

“…In a sample of women from the same study, Richards et al then measured anti-MUC1 antibodies and found that virtually all women less than age 40 had antibodies and this percentage declined with age (4), somewhat similar to the pattern we observed. It is well established that women have MUC1 and anti-MUC1 antibodies during pregnancy and breast-feeding, presumably due to changes within the breast or uterus that alter MUC1 expression, glycosylation, or shedding (4,15,16). In addition, Hinoda et al observed antibodies specific for the peptide backbone of MUC1 in patients with ulcerative colitis and speculated that inflammation may change MUC1 glycosylation and enhance its immunogenicity (17).…”

Section: Discussionmentioning

confidence: 99%

Conditions Associated with Antibodies Against the Tumor-Associated Antigen MUC1 and Their Relationship to Risk for Ovarian Cancer

Cramer

Titus-Ernstoff²,

McKolanis³

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

125

117

View full text Add to dashboard Cite

Many cancers, including ovarian, overexpress epithelial mucin (MUC1) and promote anti-MUC1 antibodies that may correlate with more favorable prognosis. By extension, risk for ovarian cancer might be reduced by preexisting MUC1-specific immunity. We measured anti-MUC1 antibodies in 705 control women, identified events predicting antibodies, and estimated ovarian cancer risk by comparing profiles of events generating antibodies in controls with those in 668 ovarian cancer cases. Factors predicting antibodies included oral contraceptive use, breast mastitis, bone fracture or osteoporosis, pelvic surgeries, nonuse of talc in genital hygiene, and to a lesser extent intrauterine device use and current smoking. There was a significant increase in the likelihood of having anti-MUC1 antibodies from 24.2% in women with 0 or 1 condition, to 51.4% in those with five or more conditions. By the same index of events, the risk for ovarian cancer was inversely associated with number of conditions predisposing to anti-MUC1 antibodies. Compared with having experienced 0 or 1 event, the adjusted risk for ovarian cancer decreased progressively with relative risks (

show abstract

“…[8, 9], in the majority of patients with prostatic cancer [10]as well as in sporadic cases of pancreatic cancer [11], in cases of chondroid syringoma [12]and in some hematological malignancies (<5% of the cases) [8, 13]. A mild-to-moderate increase of serum CA-15.3 has been noted among normal subjects, mainly in association with aging [14], pregnancy, with no difference in relation to normal or pathological pregnancy [15]and in various nonmalignant diseases and conditions [16], while it appears that renal failure does not significantly influence serum levels of this mucin [17]. Finally, elevated CA-15.3 levels were found in about 10% of patients with liver cirrhosis [18].…”

Section: Introductionmentioning

confidence: 99%

Increased Serum CA-15.3 Levels in Patients with Megaloblastic Anemia due to Vitamin B<sub>12</sub> Deficiency

Symeonidis¹,

Kouraklis-Symeonidis²,

Apostolopoulos

et al. 2004

Oncology

View full text Add to dashboard Cite

Objectives: To estimate the usefulness of serum tumor markers’ monitoring, as predictors of gastric cancer in patients with pernicious anemia. Patients and Methods: We investigated serum levels of carcinoembryonic antigen (CEA), α-fetal protein, cancer antigen (CA)-19.9, CA-125 and CA-15.3 in 50 patients with pernicious anemia and in 24 healthy controls, matched for age and sex. In 38 patients, the evaluation was repeated 1–6 months after the correction of cobalamin deficiency. Results: All patients and controls had normal serum CEA and α-FP, and the levels of these markers as well as those of CA-125 and CA-19.9 did not differ between the two groups. All 50 patients, but only 2 controls exhibited increased serum CA-15.3, and the difference between the two groups was very significant (129.4 ± 84.9 vs. 19.8 ± 7.3 IU/ml, p < 0.001), while no difference between males and females was found. A thorough clinical examination of all patients, and mammographic study in 18 females did not reveal any finding suspicious of breast cancer. CA-15.3 levels were positively correlated with serum lactate dehydrogenase, and negatively with B₁₂ and hemoglobin, but they were substantially decreased after the correction of anemia, in all 38 patients tested, and in 33 of them they were restored to normal. After a median follow-up of 34 months, one patient developed a colon cancer, but none showed any sign suspicious of breast cancer. Conclusions: Serum CA-15.3 shows an aberrant increase in untreated patients with pernicious anemia, which is reversed after the correction of the anemia. The possible origin seems unrelated to mammary tissue, and may be released by the apoptosing bone marrow megaloblastic erythroblasts.

show abstract

Maternal Serum CA125 and CA15-3 Antigen Levels in Normal and Pathological Pregnancy

Cited by 58 publications

References 13 publications

Mining the Immune Cell Proteome to Identify Ovarian Cancer-Specific Biomarkers

Mining the Immune Cell Proteome to Identify Ovarian Cancer-Specific Biomarkers

Conditions Associated with Antibodies Against the Tumor-Associated Antigen MUC1 and Their Relationship to Risk for Ovarian Cancer

Increased Serum CA-15.3 Levels in Patients with Megaloblastic Anemia due to Vitamin B<sub>12</sub> Deficiency

Contact Info

Product

Resources

About